Market Research Logo

Product and Pipeline Analysis of the Global Colorectal Cancer Market

Product and Pipeline Analysis of the Global Colorectal Cancer Market

Market Potential

According to the World Health Organization (WHO), colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. WHO reported that approximately 􂀀 Million CRC cases have been diagnosed worldwide in 2015. The National Cancer Institute (NCI) reported the number of incidences of CRC cases in the United States in 2015 is approximately 􂀀, with over 􂀀 deaths. At the time of diagnosis, 􂀀% of CRC cases are metastatic.

In the United States in 2015, CRC is the fourth leading cause of cancer, according to the American Cancer Society (ACS).

CRC is classified not only by tissue origin but by tumor mutation.

Treatment outcomes are increasingly under the microscope of the payers as additional expensive innovative chemotherapeutic agents are being launched. In the near future, drugs paired with diagnostic biomarker tests (which link patients likely to respond to specific therapies) to the given therapies will drive future targeted chemotherapy choices.

In addition, the body’s innate immune system’s response to tumors (tumor promoting versus tumor supressing) is playing a role in the treatment of CRC. Already approved immunotherapy drugs targeting programmed death-ligand 1 (PD-L1), which has prolonged survival in patients with melanoma, are presently being tested in CRC patients.

About this report

Research Overview

This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:

targeted therapies

cytotoxics

cancer vaccines

other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).

The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.

Market Overview

Strong drug pipeline continues to expand

The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.

Colorectal cancer care edges toward personalisation

With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).

Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.


  • Executive Summary
    • Physician Treatment Guidelines-Lines of Therapy
    • Key Trends
    • Market Opportunities
    • Companies to Watch
  • Methodology and Scope
  • Market Overview
    • Market Overview-Types of Treatment in Development
    • Market Overview-Global Incidences of CRC
    • Market Overview-US Incidence Rates by Year and Sex
    • Market Overview-Biomarker Type Segmentation
    • Market Overview-Key Mergers, Acquisitions, and Partnerships
    • Market Overview-Recent Developments
  • Revenue Forecast
    • Global CRC Market-Revenue Forecast
      • Table Total CRC Market: Revenue Forecast, Global, 2014-2021
    • Revenue Forecast Discussion
  • Competitive Landscape
    • Competitive Landscape Overview
    • Competitive Landscape-Phase III to Launch
    • Competitive Landscape-Phase II
    • Competitive Landscape-Phase I
  • Marketed Products
    • Key Marketed Products
  • Pipeline Drugs Analysis
    • Pipeline Synopsis-Phase III
    • Pipeline Synopsis-Phase II
    • Pipeline Synopsis-Phase I
    • Competitive Landscape-Pivotal Phase III Trials
    • Timeline of Key Events
    • Patent Expirations
    • Pipeline Discussion
  • Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug Candidates
    • Product Dashboard: Avastin (Bevacizumab)-Genentech Inc. (Roche Group)
    • Avastin (Genentech, Roche)-SWOT Analysis
    • Product Dashboard-BBI503: Boston Biomedical
    • BBI503 (Boston Biomedical)-SWOT Analysis
    • Product Dashboard-Cyramza (ramicirumab): Eli Lilly
    • Cyramza (ramicirumab) (Eli Lilly)-SWOT Analysis
    • Product Dashboard-Erbitux (cetuximab): Eli Lilly/BMS/Merck
    • Erbitux (Eli Lilly, BMS, and Merck)-SWOT Analysis
    • Product Dashboard-Imprime PGG: Biothera
    • Imprime PGG (Biothera)-SWOT Analysis
    • Product Dashboard-Lonsurf (TAS-102): Taiho (Otsuka)
    • Lonsurf (TAS-102) (Taiho, Otsuka)-SWOT Analysis
    • Product Dashboard-MGN1703: Mologen
    • MGN1703 (Mologen)-SWOT Analysis
    • Product Dashboard-Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
    • Nintedanib (BIBF-1120, OFEV) (BI)-SWOT Analysis
    • Product Dashboard-Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
    • Stivarga (Bayer, Onyx)-SWOT Analysis
    • Product Dashboard-Zaltrap (aflibercept): Sanofi
    • Zaltrap (aflibercept) (Sanofi)-SWOT Analysis
  • Conclusions
    • The Last Word-3 Big Predictions
    • The Last Word-Discussion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report